FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Maintains Hold Opinion On Shares Of Magna International Inc.

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our 12-month target by CAD14 to CAD88, based on a 2027 P/E of 9.2x, which represents a justified discount to the stock's 10-year average forward P/E of 10.7x. We maintain our adjusted EPS estimates of USD6.70 for 2026 and USD7.10 for 2027. MG posted Q1 adjusted EPS of USD1.38 versus USD0.78 in Q1 2025 (+77% Y/Y), well ahead of the USD1.01 consensus. The beat was driven by much stronger-than-expected sales and margins: revenue rose 3.1% to USD10.38B (USD110M above consensus), and adjusted EBIT margin expanded 190 bps to 5.4% (120 bps above consensus). While the company did not raise full-year EPS guidance, we think a raise is now more likely given the magnitude of the beat. Given MG's broad product diversification across the automotive parts and equipment space, and its status as the largest North American auto supplier, we think the strength of its Q1 results has positive implications for the broader sub-industry, which has been struggling from a performance standpoint given macroeconomic concerns.

Related Articles

Research

Research Alert: CFRA Keeps Hold Rating On Shares Of Baxter International Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our price target to $19 from $23, using a forward P/E of 9.5x our 2027 EPS view, a sizable discount to BAX's 10-year historical forward average. We slightly adjust our 2026 EPS estimate to $2.00 from $1.96 and maintain our 2027 EPS estimate at $1.99. Baxter delivered mixed Q1 results that reflected ongoing operational challenges despite management's transformation efforts, in our view. Sales of $2.7 billion rose 3% on a reported basis but declined 1% organically. EPS was $0.36, a 35% Y/Y decrease from the prior year, reflecting significant headwinds from tariffs, higher manufacturing costs, and an unfavorable comparison with Q1 2025. We think that BAX could be in the early stages of a turnaround focused on stabilizing the business and strengthening the balance sheet. Yet, we see the potential for a slowdown in U.S. hospital capital spending due to macroeconomic uncertainties along with continued softer demand for inhaled anesthesia products globally as important risks.

$BAX
Research

Research Alert: CFRA Maintains Strong Buy Opinion On Shares Of Rocket Lab Corporation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price to $100 from $80, applying an EV/sales multiple of 45.8x to our 2027 estimate. This multiple is a slight premium to its five-year historical average multiple at 43.1x. We raise our 2026 loss per share estimate to -$0.11 from -$0.18 and cut 2027's EPS estimate to $0.05 from $0.14. Despite the Stage 1 tank setback, Neutron development showed meaningful progress. Multiple critical subsystems passed qualification during the quarter, including the Hungry Hippo fairing, thrust structure, and Stage 2. Flight hardware is now arriving at the Wallops launch site for final integration and testing. First launch is now targeted for Q4 2026. RKLB is not waiting for the first flight to build subsequent vehicles. Management noted that production of additional Neutron tail numbers is already underway, which means follow-on flights will not be delayed by the same duration as the first launch.

$RKLB
Research

Research Alert: CFRA Reiterates Sell Rating On Shares Of Udr, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We think UDR will be an underperformer versus the S&P 500, and the trust's fundamental outlook is low-single digit growth at best. We keep our $34 target using a forward P/FFO of 13.3x below peer group given its high concentration in Sun Belt markets. We keep our 2026 FFO estimate at $2.55 and lower 2027's by $0.01 to $2.60 on revenue projections of $1.72B and $1.77B, respectively. We think this puts added pressure on UDR's ability to raise rental rates, especially for new leases where incentives like free months are still needed. Renewal leasing also faces some limitations to how much UDR can raise rents as tenants can relocate to competitor housing. Cash NOI outlook is not promising. An important metric to monitor is cash NOI, which takes into account rental revenue less operating expenses that have risen at a faster pace (higher labor, insurance, and property taxes). UDR's 2026 targets are same-store revenue growth of 0.25% to 2.25%, expense growth of 3.00% to 4.50%, and cash NOI growth of -1.00% to 1.25%.

$UDR